HER2-Low Breast Cancer: Now and in the Future

被引：6

作者：

Kang, Sora ^{[1
]}

Kim, Sung-Bae ^{[2
]}

机构：

[1] Chungnam Natl Univ Hosp, Dept Internal Med, Div Hemato oncol, Daejeon, South Korea

[2] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Oncol, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea

来源：

CANCER RESEARCH AND TREATMENT | 2024年 / 56卷 / 03期

关键词：

Breast neoplasms; HER2-low; DS-8201a; ANTIBODY-DRUG CONJUGATE; TRASTUZUMAB DERUXTECAN; SACITUZUMAB GOVITECAN; ANTITUMOR-ACTIVITY; NEOADJUVANT CHEMOTHERAPY; EXPRESSION; EFFICACY; INHIBITOR; EVOLUTION; DS-8201A;

D O I：

10.4143/crt.2023.1138

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Breast cancer is a heterogeneous disease, and its subtypes are characterized by hormone receptor and human epidermal growth factor receptor 2 (HER2) expression status. "HER2-low" tumors, which exhibit a low level of HER2 expression (immunohistochemistry 1+ or 2+ without gene amplification), were conventionally considered not amenable to anti-HER2 targeting agents based on the results of a phase III trial of trastuzumab. However, this perspective is being challenged by the emergence of novel anti-HER2 antibody-drug conjugates, such as trastuzumab-deruxtecan. These innovative therapies have demonstrated remarkable efficacy against HER2-low breast cancer, shedding new light on a previously overlooked category of breast cancer. Such promising results highlight the need for in-depth investigations of the biology and prognostic implications of HER2-low tumors. In this review, we comprehensively summarize the current evidence surrounding this topic and highlight areas that warrant further exploration and research in the future.

引用

页码：700 / 720

页数：21

共 112 条

[1] Mechanisms of Resistance to Antibody-Drug Conjugates [J].

Abelman, Rachel Occhiogrosso ;

Wu, Bogang ;

Spring, Laura M. ;

Ellisen, Leif W. ;

Bardia, Aditya .

CANCERS, 2023, 15 (04)

[2] HER2-Low Breast Cancer: Molecular Characteristics and Prognosis [J].

Agostinetto, Elisa ;

Rediti, Mattia ;

Fimereli, Danai ;

Debien, Veronique ;

Piccart, Martine ;

Aftimos, Philippe ;

Sotiriou, Christos ;

de Azambuja, Evandro .

CANCERS, 2021, 13 (11)

[3] Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer [J].

Almstedt, Katrin ;

Krauthauser, Lisa ;

Kappenberg, Franziska ;

Wagner, Daniel-Christoph ;

Heimes, Anne-Sophie ;

Battista, Marco J. J. ;

Anic, Katharina ;

Krajnak, Slavomir ;

Lebrecht, Antje ;

Schwab, Roxana ;

Brenner, Walburgis ;

Weikel, Wolfgang ;

Rahnenfuehrer, Joerg ;

Hengstler, Jan G. G. ;

Roth, Wilfried ;

Hasenburg, Annette ;

Stewen, Kathrin ;

Schmidt, Marcus .

CANCERS, 2023, 15 (05)

[4] Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer [J].

Almstedt, Katrin ;

Heimes, Anne-Sophie ;

Kappenberg, Franziska ;

Battista, Marco J. ;

Lehr, Hans-Anton ;

Krajnak, Slavomir ;

Lebrecht, Antje ;

Gehrmann, Mathias ;

Stewen, Kathrin ;

Brenner, Walburgis ;

Weikel, Wolfgang ;

Rahnenfuehrer, Joerg ;

Hengstler, Jan G. ;

Hasenburg, Annette ;

Schmidt, Marcus .

EUROPEAN JOURNAL OF CANCER, 2022, 173 :10-19

[5] Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer [J].

Alves, Fatima R. ;

Gil, Lucia ;

de Matos, Leonor Vasconcelos ;

Baleiras, Ana ;

Vasques, Carolina ;

Neves, Maria Teresa ;

Ferreira, Andre ;

Fontes-Sousa, Mario ;

Miranda, Helena ;

Martins, Ana .

CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)

[6] The dynamics of HER2-low expression during breast cancer progression [J].

Anderson, Sarah ;

Bartow, Brooke Baxter ;

Siegal, Gene P. ;

Huang, Xiao ;

Wei, Shi .

BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (03) :437-446

[7] Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, 3 trial [J].

Andre, Fabrice ;

Park, Yeon Hee ;

Kim, Sung-Bae ;

Takano, Toshimi ;

Im, Seock-Ah ;

Borges, Giuliano ;

Lima, Joao Paulo ;

Aksoy, Sercan ;

Gavila Gregori, Joaquin ;

De Laurentiis, Michelino ;

Bianchini, Giampaolo ;

Roylance, Rebecca ;

Miyoshi, Yasuo ;

Armstrong, Anne ;

Sinha, Rajni ;

Ruiz Borrego, Manuel ;

Lim, Elgene ;

Ettl, Johannes ;

Yerushalmi, Rinat ;

Zagouri, Flora ;

Duhoux, Francois P. ;

Fehm, Tanja ;

Gambhire, Dhiraj ;

Cathcart, Jillian ;

Wu, Cai ;

Chu, Changan ;

Egorov, Anton ;

Krop, Ian .

LANCET, 2023, 401 (10390) :1773-1785

[8] Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study [J].

Banerji, Udai ;

van Herpen, Carla M. L. ;

Saura, Cristina ;

Thistiethwaite, Fiona ;

Lord, Simon ;

Moreno, Victor ;

Macpherson, Iain R. ;

Boni, Valentina ;

Rolfo, Christian ;

de Vries, Elisabeth G. E. ;

Rottey, Sylvie ;

Geenen, Jilt ;

Eskens, Ferry ;

Gil-Martin, Marta ;

Mommers, Ellen C. ;

Koper, Norbert P. ;

Aftimos, Philippe .

LANCET ONCOLOGY, 2019, 20 (08) :1124-1135

[9] Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer [J].

Bansal, Rani ;

McGrath, Julie ;

Walker, Phil ;

Bustos, Matias A. ;

Rodriguez, Estelamari ;

Sammons, Sarah L. ;

Accordino, Melissa K. ;

Meisel, Jane ;

Gatti-Mays, Margaret ;

Hsu, Emily ;

Lathrop, Kate I. ;

Kaklamani, Virginia ;

Oberley, Matthew ;

Korn, W. Michael ;

Graff, Stephanie L. .

CANCER RESEARCH, 2023, 83 (05)

[10] Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial [J].

Bardia, A. ;

Jhaveri, K. ;

Im, S. A. ;

Simon, S. Pernas ;

De laurentiis, M. ;

Wang, S. ;

Martinez, N. ;

Borges, G. Santos ;

Cescon, D. W. ;

Hattori, M. ;

Lu, Y. S. ;

Hamilton, E. P. ;

Zhang, Q. Y. ;

Tsurutani, J. ;

Kalinsky, K. ;

Xu, L. ;

Denduluri, N. ;

Rugo, H. S. ;

Xu, B. ;

Pistilli, B. .

ANNALS OF ONCOLOGY, 2023, 34 :S1264-S1265

← 1 2 3 4 5 6 7 8 9 10 →